Literature DB >> 7947293

John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study.

T Koster1, F R Rosendaal, E Briët, J P Vandenbroucke.   

Abstract

Because the relationship between factor XII deficiency and venous thrombosis is unclear and study results seem contradictory, we undertook a population-based case-control study. Among 350 unselected patients younger than 70 years, with a first, objectively confirmed, episode of deep-vein thrombosis and without underlying malignant disease we detected a 6% frequency (21/350 patients) of factor XII deficiency (activity level < 57%). Among 350 healthy control subjects, matched for age and sex, the frequency was 5% (18 subjects). Thus there is no increase in prevalence of factor XII deficiency among thrombosis patients and no increase in thrombosis risk for subjects with low factor XII levels (matched odds ratio 1.2 (95% CI 0.6-2.4)). In addition, there was no relation between strata of factor XII levels and thrombosis risk. In conclusion, we do not consider factor XII to be a determinant of deep-vein thrombosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947293     DOI: 10.1111/j.1365-2141.1994.tb04937.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  27 in total

Review 1.  Hageman factor, platelets and polyphosphates: early history and recent connection.

Authors:  J Caen; Q Wu
Journal:  J Thromb Haemost       Date:  2010-04-30       Impact factor: 5.824

2.  Relationship between factor XII deficiency and thrombosis: the debate is still open?

Authors:  Gianfranco Lessiani; Angela Falco; Elvira Nicolucci; Giancarlo Rolandi; Giovanni Davì
Journal:  J Thromb Thrombolysis       Date:  2009-04-08       Impact factor: 2.300

3.  The association of a mild FXII deficiency with myocardial infarction and venous thrombosis is completely unjustified.

Authors:  Antonio Girolami; Pamela Scarparo; Silvia Vettore
Journal:  J Thromb Thrombolysis       Date:  2009-03-13       Impact factor: 2.300

Review 4.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

Review 5.  Pregnancies and oral contraceptive therapy in severe (homozygons) FXII deficiency: a study in 12 patients and review of the literature.

Authors:  A Girolami; N Zocca; B Girolami; A M Lombardi; F Fabris
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

6.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

7.  Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis.

Authors:  Erik I Tucker; Norah G Verbout; Philberta Y Leung; Sawan Hurst; Owen J T McCarty; David Gailani; András Gruber
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

Review 8.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 9.  Factor XI and XII as antithrombotic targets.

Authors:  Felicitas Müller; David Gailani; Thomas Renné
Journal:  Curr Opin Hematol       Date:  2011-09       Impact factor: 3.284

Review 10.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.